华特达因(000915) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥324,257,077.01, representing a 1.40% increase compared to ¥319,791,327.93 in the same period last year[6]. - Net profit attributable to shareholders for Q1 2020 was ¥49,564,128.20, a significant increase of 107.21% from ¥23,919,638.68 in the previous year[6]. - The net profit after deducting non-recurring gains and losses was ¥47,269,118.36, up 99.99% from ¥23,635,184.96 year-on-year[6]. - Basic and diluted earnings per share for Q1 2020 were both ¥0.21, reflecting a 110.00% increase from ¥0.10 in the previous year[6]. - Revenue from sales of goods and services rose by 51.60% to ¥437,902,139.10, attributed to increased sales collections from Dain Pharmaceutical[21]. - The total comprehensive income for Q1 2020 was CNY 94,077,184.44, significantly higher than CNY 38,834,098.17 in the previous year, indicating an increase of about 142.5%[49]. Cash Flow - The net cash flow from operating activities was ¥95,340,929.80, a recovery from a negative cash flow of -¥76,705,465.97 in the same period last year[6]. - Cash flow from operating activities generated a net inflow of CNY 95,198,529.80, a turnaround from a net outflow of CNY -76,705,465.97 in the previous year[53]. - The cash inflow from investment activities totaled CNY 177,084,383.01, compared to CNY 100,670,334.83 in the previous year, marking an increase of about 75.8%[53]. - The total cash outflow from investing activities was 341,129,303.24, significantly higher than 120,622,877.97 in the previous year, resulting in a net cash flow from investing activities of -184,286,170.23[59]. - The company had a cash and cash equivalents balance of 133,402,255.97 at the end of the period, down from 310,691,848.73 a year earlier, reflecting a net decrease of -199,683,226.68[59]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,176,633,507.33, a 0.77% increase from ¥3,152,463,167.36 at the end of the previous year[6]. - Total liabilities decreased to ¥515,409,824.96 from ¥585,316,669.43, a reduction of about 11.91%[37]. - Current liabilities totaled ¥439,318,180.47, down from ¥508,903,339.91, showing a decrease of approximately 13.65%[37]. - Shareholders' equity increased to ¥2,661,223,682.37 from ¥2,567,146,497.93, reflecting a growth of about 3.67%[39]. - The company reported a significant increase in accounts receivable, which rose to ¥258,199,662.45 from ¥283,304,362.32, indicating a decrease of about 8.87%[35]. Investments and Income - The company reported non-operating income of ¥2,295,009.84 during the reporting period[9]. - Investment income rose by 60.75% to ¥1,075,583.01, resulting from higher returns on bank wealth management products and structured deposits[19]. - The company received cash from investment redemption of ¥176,000,000.00, a 76.00% increase compared to the previous period[21]. - Other income increased by 64.23% to ¥2,256,414.56, mainly due to an increase in government subsidies recognized during the period[19]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,599[10]. - The company reported a significant increase in minority shareholders' profit by 198.46% to ¥44,513,056.24, reflecting the profit growth of Dain Pharmaceutical[21]. Changes in Control and Standards - The actual controller of the company changed from Shandong University to the State-owned Assets Supervision and Administration Commission of the Shandong Provincial Government[22]. - The company is implementing new revenue and leasing standards starting in 2020, which may impact future financial reporting[62]. - The company implemented a new revenue recognition standard starting January 1, 2020, adjusting the presentation of "prepayments" to "contract liabilities"[66].